Short interest for Omnicell gives investors a sense of the degree to which investors are betting on the decline of Omnicell's stock. Short interest data is updated every two weeks.

Omnicell Stock (NASDAQ:OMCL), Short Interest Report

Omnicell

Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACLX

ACXP

AIRE

ALPN

AUDC

AVNW

AWRE

BHIL

CARS

CFLT

CLLS

CNTB

CRAI

CROX

DASH

DRIO

EGHT

ERII

FROG

FSLY

HOWL

HYZN

INFA

JAKK

JOBY

LMDX

LMND

LOCL

LSPD

LYFT

MCRB

NARI

NVST

OLIT

OMCL

OMGA

OPEN

OTLK

PBLA

PCOR

PKOH

PLPC

PLTR

POET

PTVE

PYPL

QCOM

QNST

RCKY

RELY

ROKU

RVLV

SABR

SBGI

SEDG

SGMO

SHOP

STAA

TENB

THTX

VIRI

XRAY

Gainers


	OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.


Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Health Care

Options

General

Omnicell Inc. (NASDAQ: OMCL) experienced notable options activity. The majority of the trading volume centered around a single trade involving 300 contracts at a strike price of $60, with a premium of $83,967 and an expiration of 52 days from the trade date.

Omnicell Inc. Unusual Options Activity: Slightly OTM Call Buying With Relative Size

Ai,,Machine,Learning,,Hands,Of,Robot,And,Human,Touching,On

Analyst Color

Biotech

Large Cap

Long Ideas

Sector ETFs

Specialty ETFs

Economics

Analyst Ratings

Tech

ETFs

AAPL

ABBNY

BOTZ

EQIX

IBKR

ISRG

LPLA

NVDA

TECB

TSLA

Top Investment Bank Unveils 3 ETFs, 10 Stocks To Buy In The AI Boom

Omnicell Inc

Benchmark analyst Bill Sutherland reiterates Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and maintains $38 price target.

Price Target

Reiteration

Benchmark Reiterates Buy on Omnicell, Maintains $38 Price Target

The table below summarizes Omnicell&#39;s second quarter and full year 2024 guidance outlined above.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Q2 2024
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Bookings
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$750 million - $875 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Total Revenues
</td>
<td colspan="1" rowspan="1">
$250 million - $260 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1.045 billion - $1.120 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Product Revenues
</td>
<td colspan="1" rowspan="1">
$140 million - $145 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$605 million - $650 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Service Revenues
</td>
<td colspan="1" rowspan="1">
$110 million - $115 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$440 million - $470 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Technical Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Advanced Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP EBITDA
</td>
<td colspan="1" rowspan="1">
$14 million - $20 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$90 million - $120 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Earnings Per Share
</td>
<td colspan="1" rowspan="1">
$0.10 - $0.20
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$0.90 - $1.40
</td>
</tr>
</tbody>
</table>
&nbsp;

Guidance

Omnicell Reaffirms FY24 Outlook: Adj EPS $0.90-1.40 vs $1.07 Est; Sees Sales $1.045B-1.120B vs $1.06B Est

The table below summarizes Omnicell&#39;s second quarter and full year 2024 guidance outlined above.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Q2 2024
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Bookings
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$750 million - $875 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Total Revenues
</td>
<td colspan="1" rowspan="1">
$250 million - $260 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1.045 billion - $1.120 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Product Revenues
</td>
<td colspan="1" rowspan="1">
$140 million - $145 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$605 million - $650 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Service Revenues
</td>
<td colspan="1" rowspan="1">
$110 million - $115 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$440 million - $470 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Technical Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Advanced Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million - $235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP EBITDA
</td>
<td colspan="1" rowspan="1">
$14 million - $20 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$90 million - $120 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Earnings Per Share
</td>
<td colspan="1" rowspan="1">
$0.10 - $0.20
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$0.90 - $1.40
</td>
</tr>
</tbody>
</table>

Omnicell Q2 Outlook: Total Revenues $250M - $260M Vs. $261.88M Estimate, Adj. EPS $0.10-$0.20 Vs. $0.27 Estimate

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.09) by 133.33 percent. This is a 92.31 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $246.150 million which beat the analyst consensus estimate of $236.754 million by 3.97 percent. This is a 15.30 percent decrease over sales of $290.629 million the same period last year.

Earnings

Earnings Beats

Omnicell Q1 2024 Adj EPS $0.03 Beats $(0.09) Estimate, Sales $246.150M Beat $236.754M Estimate

Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. &nbsp;
Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to medium-sized companies, Mr. Kuipers brings over 25 years of technology leadership experience to the CFO role at Clover. As the former Executive Vice President and CFO at Omnicell, Inc., a healthcare technology company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>), Mr. Kuipers provided financial leadership and strategic vision, contributing to the company's growth from $485 million to $1.3 billion in revenue. Beyond the CFO function, Mr. Kuipers oversaw various other critical functions, including global supply chain &amp; manufacturing, information technology, international business, corporate development, and M&amp;A, playing a pivotal role in transforming Omnicell into a cloud-based platform and SaaS/Tech-Enabled Services market leader.
Prior to his role at Omnicell, Mr. Kuipers served as the CFO at Quantcast and The Weather Company, where he provided financial leadership driving profitable revenue growth through capital allocation, digital platform development, and global expansion. His extensive background also includes divisional CFO and executive FP&amp;A leadership roles at Yahoo!, Altera Corporation (acquired by Intel), General Electric Company, and Akzo Nobel, where he implemented financial management strategies and operating rigor to drive business execution at scale.
Mr. Kuipers started his career with nearly a decade at Ernst &amp; Young where he focused on financial audits, IPO services, and M&amp;A due diligence for multinational companies. He received a Master's Degree in Economics and Business Administration from the Maastricht University School of Business and Economics, and is a Chartered Accountant in the Netherlands.
"We are thrilled to welcome Peter to Clover as our new Chief Financial Officer," said Andrew Toy, Chief Executive Officer, Clover Health. "His extensive experience as a public company Chief Financial Officer and strong leadership skills make him the perfect fit to lead our finance team as we look to achieve Adjusted EBITDA profitability for 2024, and then embark on our next phase of growth."
In his role as CFO, Kuipers will be responsible for overseeing all financial aspects of the Company, including budgeting, forecasting, financial reporting, and capital management. He will play a pivotal role in driving financial performance and implementing strategies to optimize operational efficiency.
"I am honored to join Clover at such an exciting time in its journey," said Peter Kuipers. "I have always believed in the ability of technology to fundamentally transform an industry and Clover has shown that with its platform, it has a unique approach that can power profitability and growth in a differentiated way. I'm thrilled to be part of the team that will be focused on bringing that capability to care for as many people as possible."

Management

CLOV

Clover Health Appoints Peter Kuipers As Chief Financial Officer, Effective As Of The Day After The Filing Of The Co's Quarterly Report On Form 10-Q For The Quarter-Ended March 31, 2024

Multi-year Innovation Program Designed to Maximize Value and Outcomes for XT Automated Dispensing System
Omnicell, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced XT Amplify, a multi-year innovation program that is intended to maximize value for hospitals, health systems, and post-acute care facilities that have invested in Omnicell's XT Automated Dispensing System while also seeking to drive enhanced clinical and operational outcomes at the points of care and within pharmacies.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240416872419/en/">https://www.businesswire.com/news/home/20240416872419/en/</a>
"We recognize that some of our customers are navigating difficult operational and economic environments. We believe Omnicell is nicely positioned to address these current challenges while adapting for the future," said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. "We are confident the XT Amplify program will deliver continuous innovation that addresses these evolving and complex needs, while helping customers to maximize outcomes and the value of Omnicell automated dispensing systems currently in use around the globe."
The solutions within the multi-year XT Amplify program are intended to enhance nursing efficiency, reduce medication errors and waste, and, ultimately, help health systems achieve the aspirational outcomes outlined in the industry-defined vision of the Autonomous Pharmacy. The first set of solutions that will be available in North America include:
XTExtend: This comprehensive console swap is intended to provide a high level of security while enhancing the user experience. Designed to be backward compatible, the console aims to strengthen interoperability within the healthcare facility, while maximizing value of current technology.
MedChill: Intended to improve the safety and security of individual, temperature-controlled medications, this secure device for compatible refrigeration supports item-level inventory visibility that is designed to maximize expiration dates to reduce waste and stockouts at the points of care and within pharmacies.
SupplyXpert: This inventory management software is designed to manage medical supplies housed within the XT Supply cabinet and open-shelf locations, providing insights into stockout events, stock value, key performance indicators, and optimization recommendations. This should extend the benefits of existing equipment while helping customers manage the increasing costs of medical supplies.
ServerScale: The on-premises OmniCenter virtual server solution is now available in a subscription format, that is intended to allow customers to stay current with the latest operating systems in an effort to ensure infrastructure readiness today, while providing a foundation for the evolving and expanding health system.
CarePlus: Omnicell's market-leading automation solutions are now supported by expert services that are designed to improve solution adoption and provide data-driven performance optimization information that is expected to enhance nursing and pharmacy efficiency.
XT Amplify is intended to enable all healthcare facilities, regardless of where they are in their adoption and utilization of Omnicell's XT Automated Dispensing System, to solve important challenges today and into the future.
"We recognize the value of technology-driven medication management. But installing a new infrastructure and the change management that comes with that can be very challenging," said Jennifer Hillman, PharmD, executive director of Pharmacy at San Antonio-based University Health. "XT Amplify provides us a path to implement innovative new solutions while maximizing the value of our existing technology investments."
XT Amplify is designed to support healthcare facilities as they advance toward the industry-defined vision of the Autonomous Pharmacy that seeks to replace manual, error-prone activities with automated processes that are intended to be safer and more efficient. To learn more, visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fomnicell.com%2FXTAmplify&amp;esheet=53933329&amp;newsitemid=20240416872419&amp;lan=en-US&amp;anchor=omnicell.com%2FXTAmplify&amp;index=1&amp;md5=5b04c70db927e9df3aa6a9905766f8e7">omnicell.com/XTAmplify</a>.

Omnicell Announces XT Amplify, A Multi-Year Innovation Program That Is Intended To Maximize Value For Hospitals, Health Systems, And Post-Acute Care Facilities That Have Invested In Omnicell's XT Automated Dispensing System

Benchmark analyst Bill Sutherland maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Buy and lowers the price target from $42 to $38.

Benchmark Maintains Buy on Omnicell, Lowers Price Target to $38

Wells Fargo analyst Stan Berenshteyn maintains Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) with a Equal-Weight and lowers the price target from $28 to $26.

Wells Fargo Maintains Equal-Weight on Omnicell, Lowers Price Target to $26

WIIM

Omnicell shares are trading lower after the company reported fourth-quarter financial results and issued guidance below estimates.

The table below summarizes Omnicell&#39;s 2024&nbsp;guidance&nbsp;outlined above.
<table cellspacing="0">
<tbody>
<tr>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
Q1&nbsp;2024
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Bookings
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$750 million&nbsp;-&nbsp;$875 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Total Revenues
</td>
<td colspan="1" rowspan="1">
$232 million&nbsp;-&nbsp;$242 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$1.045 billion&nbsp;-&nbsp;$1.120 billion
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Product Revenues
</td>
<td colspan="1" rowspan="1">
$128 million&nbsp;-&nbsp;$133 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$605 million&nbsp;-&nbsp;$650 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Service Revenues
</td>
<td colspan="1" rowspan="1">
$104 million&nbsp;-&nbsp;$109 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$440 million&nbsp;-&nbsp;$470 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Technical Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million&nbsp;-&nbsp;$235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Advanced Services Revenues
</td>
<td colspan="1" rowspan="1">
Not provided
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$220 million&nbsp;-&nbsp;$235 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP EBITDA
</td>
<td colspan="1" rowspan="1">
($2)&nbsp;million -&nbsp;$4 million
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$90 million&nbsp;-&nbsp;$120 million
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Non-GAAP Earnings Per Share
</td>
<td colspan="1" rowspan="1">
($0.10)&nbsp;-&nbsp;$0.00
</td>
<td colspan="1" rowspan="1">
&nbsp;
</td>
<td colspan="1" rowspan="1">
$0.90&nbsp;-&nbsp;$1.40
</td>
</tr>
</tbody>
</table>

Omnicell Expects Q1 Revenue of $232M-$242M Vs $262.37M Est, Adj EPS of ($0.10)-$0.00 Vs $0.31 Est, FY24 Revenue of $1.045B-$1.120B Vs $1.08B Est, Adj EPS of $0.90-$1.40 Vs $1.66 Est

Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.15 by 120 percent. This is unchanged from the same period last year. The company reported quarterly sales of $258.85 million which beat the analyst consensus estimate of $255.56 million by 1.29 percent. This is a 13.04 percent decrease over sales of $297.67 million the same period last year.

Omnicell Q4 Adj EPS $0.33 Beats $0.15 Estimate, Sales $258.85M Beat $255.56M Estimate

AFRM

AIRC

APDN

ARES

AXTA

BILL

BIOX

CIGI

CIVB

CLSK

CPRI

CRIS

CTLP

CTRE

CYBR

DOCS

DXCM

EGAN

EMKR

EXPE

FARM

FLUX

FORR

GTES

IBEX

IIIV

ILMN

IRMD

JRSH

KVUE

LADR

LITE

LIVE

LPTH

LQDT

LTRX

LVWR

NGVC

ONTO

PATK

PCTY

PEAK

PECO

PETS

PINE

PINS

PODC

Earnings Scheduled For February 8, 2024

Piper Sandler upgraded its rating of Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) to Overweight with a price target of $39.00, changing its price target from $70.00 to $39.00.
Shares of Omnicell are trading up 1.81% over the last 24 hours, at $29.77 per share.
A move to $39.00 would account for a 31.0% increase from the current share price.
<h3>About Omnicell</h3>
Omnicell Inc provides automation and business analytics software for healthcare providers. The automation and analytics segment manufactures medication dispensing systems, pharmacy inventory management systems, and related software. The medication adherence segment sells products like consumable medication blister cards and packaging equipment to help administer medication outside of a hospital setting. Omnicell generates the vast majority of its revenue in the United States.
<h3>About Analyst Ratings</h3>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Piper Sandler Upgrades Omnicell: Here's What You Need To Know

Wells Fargo analyst Stan Berenshteyn upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Underweight to Equal-Weight and lowers the price target from $39 to $28.

Upgrades

Wells Fargo Upgrades Omnicell to Equal-Weight, Lowers Price Target to $28

BTIG analyst David Larsen downgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Buy to Neutral.

Downgrades

BTIG Downgrades Omnicell to Neutral

Piper Sandler analyst Sean Wieland upgrades Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) from Neutral to Overweight and lowers the price target from $70 to $39.

Piper Sandler Upgrades Omnicell to Overweight, Lowers Price Target to $39

<h3>Gainers</h3>
<ul>
<li>OmniLit Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olit#NASDAQ">OLIT</a>) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.</li>
<li>Panbela Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbla#NASDAQ">PBLA</a>) shares climbed 40.6% to $1.1050. Panbela announced the publication of preclinical and clinical data from studies of CPP-1X (also known as &alpha;-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes (T1D).</li>
<li>Lemonade, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lmnd#NYSE">LMND</a>) climbed 37.2% to $15.09 following strong third-quarter results.</li>
<li>Aware, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/awre#NASDAQ">AWRE</a>) shares climbed 36.2% to $1.4299 after the company reported strong quarterly sales results.</li>
<li>Alpine Immune Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alpn#NASDAQ">ALPN</a>) rose 35.4% to $14.25. The company presented initial clinical data on povetacicept in autoimmune glomerulonephritis in a late-breaking poster session at the American Society of Nephrology Kidney Week 2023.</li>
<li>Rocky Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcky#NASDAQ">RCKY</a>) gained 33.9% to $16.87 after the company reported better-than-expected third-quarter financial results.</li>
<li>8x8, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eght#NASDAQ">EGHT</a>) gained 31.2% to $3.0050 following upbeat quarterly results.</li>
<li>Kodiak Sciences Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kod#NASDAQ">KOD</a>) jumped 30.8% to $2.0150 after the company said data from tarcocimab tedromer will be presented during the annual meeting of the American Academy of Ophthalmology to be held Nov. 3-6 in San Francisco.</li>
<li>JAKKS Pacific, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jakk#NASDAQ">JAKK</a>) jumped 30% to $22.17 after the company reported better-than-expected third-quarter financial results.</li>
<li>Omega Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omga#NASDAQ">OMGA</a>) gained 26% to $1.71.</li>
<li>Roku, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roku#NASDAQ">ROKU</a>) shares surged 25.7% to $75.06 after the company reported better-than-expected third-quarter sales results.</li>
<li>AudioCodes Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/audc#NASDAQ">AUDC</a>) shares rose 24.9% to $9.78 after the company reported better-than-expected third-quarter financial results.</li>
<li>Hyzon Motors Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hyzn#NASDAQ">HYZN</a>) jumped 24.3% to $0.92.</li>
<li>Arcellx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aclx#NASDAQ">ACLX</a>) gained 23.3% to $42.42. Arcellx announced oral presentation for its CART-ddBCMA Phase 1 trial in patients with relapsed or refractory multiple myeloma at the 65th ASH Annual Meeting and Exposition.</li>
<li>Shopify Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shop#NYSE">SHOP</a>) surged 22.4% to $59.69 after the company reported better-than-expected third-quarter financial results.</li>
<li>Local Bounti Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/locl#NYSE">LOCL</a>) gained 22.2% to $2.6399.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adn#NASDAQ">ADN</a>) jumped 22% to $0.46.</li>
<li>Joby Aviation, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/joby#NYSE">JOBY</a>) climbed 21.3% to $6.50 following strong earnings.</li>
<li>Sinclair, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbgi#NASDAQ">SBGI</a>) gained 21.2% to $12.86 following quarterly results.</li>
<li>Virios Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viri#NASDAQ">VIRI</a>) gained 21.1% to $0.6240.</li>
<li>Theratechnologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thtx#NASDAQ">THTX</a>) climbed 20.2% to $1.07.</li>
<li>Pactiv Evergreen Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptve#NASDAQ">PTVE</a>) gained 19.8% to $10.22 following upbeat earnings.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) shares jumped 18.7% to $16.92 after the company reported upbeat third-quarter financial results.</li>
<li>Benson Hill, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhil#NASDAQ">BHIL</a>) rose 18.6% to $0.1963.</li>
<li>Palantir Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pltr#NYSE">PLTR</a>) surged 18.5% to $17.68 after the company reported better-than-expected third-quarter financial results and raised FY23 revenue guidance.</li>
<li>Opendoor Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) jumped 18.3% to $2.2350.</li>
<li>Pitney Bowes Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbi#NYSE">PBI</a>) gained 18.3% to $3.75 following upbeat earnings.</li>
<li>Park-Ohio Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pkoh#NASDAQ">PKOH</a>) climbed 17.9% to $27.08 following upbeat earnings.</li>
<li>DoorDash, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dash#NASDAQ">DASH</a>) gained 17.7% to $89.32 after the company reported better-than-expected third-quarter sales results.</li>
<li>Informatica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/infa#NYSE">INFA</a>) rose 17.7% to $22.55 after the company posted upbeat quarterly sales and announced a restructuring plan.</li>
<li>Energy Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/erii#NASDAQ">ERII</a>) jumped 17.5% to $16.93 following strong earnings.</li>
<li>Lightspeed Commerce Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lspd#NYSE">LSPD</a>) gained 16.5% to $14.50 after posting quarterly results.</li>
<li>Aviat Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avnw#NASDAQ">AVNW</a>) surged 15.9% to $30.67 following first-quarter results.</li>
<li>JFrog Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frog#NASDAQ">FROG</a>) climbed 15.6% to $26.07 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) rose 15.5% to $4.0450 following strong sales.</li>
<li>Avis Budget Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/car#NASDAQ">CAR</a>) gained 14.1% to $187.11 after the company posted upbeat earnings and announced management realignment.</li>
<li>Cellectis S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clls#NASDAQ">CLLS</a>) shares climbed 14% to $3.0094. Cellectis shares are jumped around 174% on Wednesday after the company announced a research agreement with AstraZeneca. The company is scheduled to report financial results for the third quarter on Nov. 6, 2023.</li>
<li>Cars.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cars#NYSE">CARS</a>) gained 13% to $17.00 following third-quarter results.</li>
<li>LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) shares rose 8.7% to $0.0889 after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting determination.</li>
<li>The Clorox Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/clx#NYSE">CLX</a>) gained 7.6% to $124.13 after the company reported better-than-expected quarterly sales results.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) gained 7.3% to $9.84.</li>
<li>QUALCOMM Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qcom#NASDAQ">QCOM</a>) gained 4.9% to $116.26 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter sales guidance above estimates.</li>
<li>PayPal Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pypl#NASDAQ">PYPL</a>) shares rose 3.9% to $53.65 following upbeat results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Outlook Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) shares fell 48.3% to $0.3268 after the FDA informed the company that an additional adequate and well-controlled clinical trial would be required for the approval of ONS-5010 for the treatment of wet AMD.</li>
<li>Confluent, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cflt#NASDAQ">CFLT</a>) fell 44.3% to $15.68 after the company reported third-quarter financial results.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) dipped 33.2% to $18.43 after the company reported mixed third-quarter financial results.</li>
<li>Acurx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acxp#NASDAQ">ACXP</a>) fell 31.4% to $3.48 after the company released efficacy results from a Phase 2 trial.</li>
<li>reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) declined 31.1% to $12.06</li>
<li>POET Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/poet#NASDAQ">POET</a>) dipped 29.4% to $1.9212 after the company initiated a public offering in the United States and a non-brokered offering in Canada.</li>
<li>Gannett Co., Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gci#NYSE">GCI</a>) fell 24.8% to $1.7290 following third-quarter results.</li>
<li>DarioHealth Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/drio#NASDAQ">DRIO</a>) declined 23.3% to $0.7746 following downbeat quarterly results.</li>
<li>Seres Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcrb#NASDAQ">MCRB</a>) fell 19.7% to $1.1550 following quarterly results.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgmo#NASDAQ">SGMO</a>) dropped 18.5% to $0.4814 following weak quarterly results.</li>
<li>Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares fell 18% to $0.7715 after declining 6% on Wednesday.</li>
<li>Connect Biopharma Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cntb#NASDAQ">CNTB</a>) declined 18% to $1.4522.</li>
<li>Omnicell, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omcl#NASDAQ">OMCL</a>) declined 17.5% to $29.51 following third-quarter results.</li>
<li>Procore Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcor#NASDAQ">PCOR</a>) shares fell 17.3% to $49.79 after the company reported third-quarter financial results and issued guidance.</li>
<li>Inari Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nari#NASDAQ">NARI</a>) declined 16.8% to $51.05 after the company reported third-quarter results and announced it will acquire LimFlow for $250 million in cash.</li>
<li>Regal Rexnord Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rrx#NYSE">RRX</a>) dipped 16.8% to $98.26 following downbeat results.</li>
<li>STAAR Surgical Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/staa#NASDAQ">STAA</a>) fell 16.5% to $36.18 following third-quarter results.</li>
<li>Preformed Line Products Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plpc#NASDAQ">PLPC</a>) declined 16.4% to $115.84 following third-quarter results.</li>
<li>Tenable Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tenb#NASDAQ">TENB</a>) fell 15.6% to $35.40 following third-quarter results.</li>
<li>Werewolf Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/howl#NASDAQ">HOWL</a>) shares fell 15.4% to $1.93 after dipping around 9% on Wednesday.</li>
<li>Sturm, Ruger &amp; Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rgr#NYSE">RGR</a>) declined 14.8% to $46.30 following weak quarterly results.</li>
<li>CRA International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crai#NASDAQ">CRAI</a>) fell 14.6% to $83.00 following weak quarterly results.</li>
<li>Belden Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bdc#NYSE">BDC</a>) declined 14.4% to $61.45 following weak fourth-quarter guidance.</li>
<li>KBR, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kbr#NYSE">KBR</a>) fell 13.5% to $50.41 following weak sales.</li>
<li>Pediatrix Medical Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/md#NYSE">MD</a>) declined 11.7% to $9.89 following weak results.</li>
<li>DENTSPLY SIRONA Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xray#NASDAQ">XRAY</a>) dropped 11.6% to $27.25 following downbeat sales.</li>
<li>Markel Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkl#NYSE">MKL</a>) declined 11.6% to $1,319.19. The company reported third-quarter financial results.</li>
<li>BorgWarner Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bwa#NYSE">BWA</a>) fell 11.4% to $32.90 after it reported third-quarter earnings.</li>
<li>Marriott Vacations Worldwide Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vac#NYSE">VAC</a>) declined 10.3% to $79.73 following quarterly results.</li>
<li>Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) fell 10.2% to $16.73 following weak earnings.</li>
<li>Envista Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvst#NYSE">NVST</a>) fell 9.5% to $20.80 after reporting weak third-quarter results.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sedg#NASDAQ">SEDG</a>) shares fell 9% to $68.95 after the company reported weaker-than-expected sales for its third quarter.</li>
<li>Crocs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crox#NASDAQ">CROX</a>) fell 8.4% to $80.06 after the company slashed its FY23 outlook.</li>
<li>Tempur Sealy International, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tpx#NYSE">TPX</a>) declined 8.3% to $37.03 following weak results.</li>
<li>AXIS Capital Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axs#NYSE">AXS</a>) dropped 7.7% to $53.44 following quarterly results.</li>
<li>Revolve Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvlv#NASDAQ">RVLV</a>) fell 5.8% to $12.71 following weak quarterly earnings.</li>
<li>QuinStreet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qnst#NASDAQ">QNST</a>) fell 4.4% to $11.15 following quarterly results.</li>
<li>Albemarle Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/alb#NYSE">ALB</a>) shares declined 3.8% to $118.30 after reporting latest-quarter results.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/11/35565159/apple-gears-up-for-q4-print-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call"> Apple Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Restructuring
Omnicell plans to take action as it relates to cost containment across the business, including a headcount reduction across our business functions, and is expecting approximately $12 million - $18 million of non-recurring restructuring and related charges related to the cost containment plan. The Company expects to incur a majority of the charges in fourth quarter of 2023 and substantially complete the plan by end of second quarter of 2024, subject to local law and consultation requirement. Annualized cost savings of $45 million - $55 million, approximately 75 percent of which are expected to be in Operating Expenses, are expected. A majority of the benefit from the cost actions is anticipated to be realized beginning in the first quarter of 2024 with a smaller portion of the savings expected as the year progresses. The cost actions should be partially offset by year over year increases in compensation and vendor price increases.

Omnicell Announces Headcount Reduction, Expects $12M-$18M In Non-Recurring Costs

For the fourth quarter of 2023, the Company expects total revenues to be between $247 million and $267 million. The Company expects fourth quarter 2023 product revenues to be between $142 million and $152 million, and fourth quarter 2023 service revenues to be between $105 million and $115 million. The Company expects fourth quarter 2023 non-GAAP EBITDA to be between $9 million and $19 million. The Company expects fourth quarter 2023 non-GAAP earnings per share to be between $0.07 and $0.22 per share.

Omnicell Sees Q4 2023 Revenue $247M-$267M Vs $299.67M Est

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Omnicell (OMCL – Research Report), AnaptysBio (ANAB ...

Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), AnaptysBio (ANAB) and LivaNova (LIVN)

Omnicell Q1 2024 Earnings Preview

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Omnicell Stock (NASDAQ:OMCL), Short Interest Report

People Also Watch